Insulet Corporation — Q3 2014 Form 10-Q
Business and period: Insulet develops, manufactures and sells the OmniPod insulin management system and other diabetes products. This unaudited report covers the quarter and nine months ended September 30, 2014; comparisons are with the same 2013 periods unless noted.
Financial performance
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $75.0 million | $61.1 million | $216.2 million | $178.6 million |
| Gross profit / margin | $38.0 million / 50.7% | $27.4 million / 44.8% | $106.6 million / 49.3% | $79.4 million / 44.5% |
| Operating loss | $2.9 million | $17.3 million | $10.0 million | $29.3 million |
| Net loss | $10.8 million | $21.3 million | $46.1 million | $42.5 million |
| Net loss per share | $0.19 | $0.39 | $0.83 | $0.79 |
| Operating cash flow | Not provided for the quarter | $4.3 million | $6.9 million |
Revenue rose 23% in Q3 and 21% for the first nine months, primarily from continued OmniPod adoption in the U.S. and internationally. Nine-month growth was partly offset by reduced Medicare mail-order testing-supply sales following the DMEPOS competitive bidding program. Gross margin improved as per-unit costs fell through material savings, supplier discounts and higher manufacturing-volume absorption. Q3 operating loss narrowed substantially; nine-month net loss increased, mainly because of debt-extinguishment charges.
Financial position and liquidity
- At September 30, 2014, cash and cash equivalents were $146.4 million, versus $149.7 million at year-end 2013. Current assets were $206.6 million and current liabilities $47.8 million.
- Long-term debt was $167.4 million carrying value, representing $201.3 million principal of 2% convertible notes due June 2019, net of a $33.8 million debt discount. Capital lease obligations totaled $7.1 million.
- Cash from operations was $4.3 million; investing cash outflow was $8.9 million, primarily for manufacturing equipment. Financing cash flow was $1.2 million, after substantial debt issuance and repayment activity. Cash declined $3.4 million during the nine months.
- Accounts receivable rose to $47.1 million from $33.1 million; management attributed the increase largely to shipment timing and customer-base growth. Two customers accounted for 18% and 14% of gross receivables.
Changes, outlook and material items
- In June 2014, Insulet issued $201.3 million principal of 2% convertible notes and repurchased most of its 3.75% notes; the remaining 3.75% notes were converted or redeemed in July. Debt-extinguishment losses totaled $23.2 million for the nine months, including $18.9 million in Q2 and $4.3 million in Q3.
- Q3 general and administrative costs included $5.2 million of accelerated stock compensation tied to an executive’s retirement and $1.4 million of severance expense. The company also recorded about $7.0 million of expense for the BD patent-litigation settlement and related legal fees; the case was dismissed with prejudice in July.
- Management expected 2014 revenue to continue increasing as the customer base expanded in the U.S. and internationally, but provided no numerical full-year guidance. It expected near-term net losses to continue and stated cash, together with expected sales cash generation, should cover projected operating and debt-service needs for at least 12 months.
- Management expected Q4 R&D spending to increase, G&A spending to decrease as executive-retirement costs do not recur, and sales and marketing spending to remain broadly consistent with current levels. Gross margin was expected to benefit from manufacturing efficiencies.
- Key risks include dependence on the OmniPod and a single-source OmniPod supplier, reimbursement and competitive-bidding changes, manufacturing and product-quality execution, competition, and the ability to reduce costs and achieve profitability. The Massachusetts Attorney General had raised allegations about historical prescription refills; Insulet disputed them and recorded a liability for an estimated potential settlement, without disclosing its amount. A Massachusetts sales-and-use-tax assessment was also under appeal with a liability recorded.
Investor verification priorities
- Confirm the source and durability of revenue growth, including OmniPod versus other diabetes-product sales; the filing does not provide a clear product-level revenue breakdown.
- Track gross-margin gains against production volumes, unit costs and reliance on Flextronics as the complete OmniPod supplier.
- Assess cash conversion and receivables collection, given the $16.7 million operating cash use from higher receivables during the nine-month period.
- Review the 2% notes’ conversion terms, future cash interest and principal obligations, and the effect of potential conversion-related dilution.
- Monitor resolution and financial exposure for the Massachusetts prescription-refill matter and sales-tax appeal, and confirm that the BD settlement fully resolves the patent dispute.
- Evaluate whether management’s 12-month liquidity assessment and path toward profitability remain supportable as operating losses and investment needs continue.